Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00349830 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. 5 versions Re-verified since May 17, 2023, no change to tracked fieldsv28-v32
  2. Primary and study completion dates: Jan 2022 to Jan 2032v27
  3. Site contact updatedv26
  4. Site contact updatedv25
  5. Site contact updatedv24
Show 22 earlier versionsHide 22 earlier versions
  1. Completion date: Jan 2022 Site contact updatedv23 Show all 2 changesShow less
    • Site contact updated
  2. Site contact updatedv22
  3. Enrollment target: 500 to 2000 Primary endpoint revised · Eligibility criteria expanded, about 3 wordsv21 Show all 3 changesShow less
    • Primary endpoint revised
    • Eligibility criteria expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  4. Site contact updatedv20
  5. 3 versions Re-verified since Feb 14, 2013, no change to tracked fieldsv17-v19
  6. Phase: Not applicable to Not specified Enrollment target: 300 to 500 · Site contact updatedv16 Show all 3 changesShow less
    • Enrollment target: 300 to 500
    • Site contact updated
  7. 3 versions Re-verified since Aug 19, 2010, no change to tracked fieldsv13-v15
  8. Site contact updatedv12
  9. Site contact updatedv11
  10. Site contact updatedv10
  11. Primary completion date: Jan 2022 Site contact updated · Eligibility criteria expanded, about 1 wordv9 Show all 3 changesShow less
    • Site contact updated
    • Eligibility criteria expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  12. Eligibility criteria revisedv8 Show moreShow less

    See this version in full on ClinicalTrials.gov ↗

  13. Re-verified, no change to tracked fieldsv7
  14. Eligibility criteria revised Study site revisedv6 Show all 2 changesShow less
    • Study site revised

    See this version in full on ClinicalTrials.gov ↗

  15. Site contact updatedv5
  16. Re-verified, no change to tracked fieldsv4
  17. Start date: Jan 2002 Eligibility criteria expanded, about 13 words · Study title expanded, about 4 wordsv3 Show all 3 changesShow less
    • Eligibility criteria expanded, about 13 words
    • Study title expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  18. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.
Trial Details
NCT Number NCT00349830
Lead Sponsor Stanford University
Conditions Carcinomas (Including Squamous Cell and Adenocarcinoma), Neoplasms
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov